Q-omics provides the consensus-scored R3HDM2P1 profile across patient tissues and cancer cell-line models. R3HDM2P1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, R3HDM2P1 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, R3HDM2P1 RNA expression shows 9,053 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, HNSC, and GBM as cancer lineages where R3HDM2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for R3HDM2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes R3HDM2P1 survival associations across molecular data types. R3HDM2P1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible R3HDM2P1 RNA expression–survival associations across cancer types. High R3HDM2P1 expression shows unfavorable associations in UCS, UCEC, COAD, MESO and SKCM, but favorable associations in KIRC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for R3HDM2P1 RNA expression.
This table summarizes R3HDM2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for R3HDM2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. R3HDM2P1 shows higher tumor expression in HNSC, KIRC and COAD. The HNSC box plot shows higher R3HDM2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.005, t-test p = .024).
This table shows molecular features associated with R3HDM2P1 in patient tissues and cancer cell lines. In patient samples, R3HDM2P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
